2026年4月, 在有关疫苗和基因疗法的争议性决定后, 林业发展局最顶尖的生物学官员Vinay Prasad博士将辞职。 Dr. Vinay Prasad, FDA's top biologics official, will resign in April 2026 after controversial decisions on vaccines and gene therapies.

林业发展局生物评价和研究中心主任Vinay Prasad博士将于2026年4月辞职, Dr. Vinay Prasad, head of the FDA’s Center for Biologics Evaluation and Research, will step down in April 2026, ending a tenure marked by regulatory controversies. 他离开后,在疫苗和基因疗法批准问题上出现了引人注目的争议,包括要求进行更多的研究以及一场有争议的亨廷顿病理治疗假外科试验。 His departure follows high-profile disputes over vaccine and gene therapy approvals, including demands for additional studies and a controversial sham surgery trial for a Huntington’s disease therapy. 普拉萨德在2025年7月短暂离开,然后在卫生部长罗伯特·肯尼迪小的支持下返回,因延误和转变指导而面临生物技术公司和患者倡导者的批评. Prasad, who briefly left in July 2025 before returning with support from Health Secretary Robert F. Kennedy Jr., faced criticism from biotech firms and patient advocates over delays and shifting guidance. 美国食品和药物管理局在最初的拒绝后,改变了Moderna的mRNA流感疫苗的使用. The FDA reversed course on Moderna’s mRNA flu vaccine after initial rejection. 普拉萨德将回到他在UCSF的学术角色。 Prasad will return to his academic role at UCSF.